Bernd Hohenstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bernd Hohenstein has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Volker J. J. Schettler
Center of Nephrology Göttingen GbR, Göttingen, Germany
3 shared publications - Claudia Goettsch
Universitätsklinikum Aachen, RWTH Aachen
2 shared publications - Henning Morawietz
Division of Vascular Endothelium and Microcirculation, Department of Medicine III, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, 01307 Dresden, Germany
2 shared publications Holger Lawall
Praxis für Herzkreislauf-Erkrankungen
2 shared publications- Irakli Kopaliani
Technische Universität Dresden
2 shared publications - Mark Dominik Alscher
Robert Bosch Krankenhaus
2 shared publications
Latest Publications
- 26 September 2025
- Published by Springer Nature
- p. 169-197
Pathophysiologie der Atherosklerose
- 5 December 2024
- Published by Springer Nature in Die Nephrologie
- Vol. 20 (1) , 26-32
Glomerulonephritis mit MPGN-Muster und verwandte Formen
- 5 December 2024
- Published by Springer Nature in Die Nephrologie
- Vol. 20 (1) , 26-32
Glomerulonephritis mit MPGN-Muster und verwandte Formen
- 1 January 2024
- Published by Springer Nature
- p. 1-29
Pathophysiologie der Atherosklerose
- 1 January 2024
- Published by Georg Thieme Verlag KG
Erkrankungen mit Befall der Glomerula
- 1 January 2024
- Published by Georg Thieme Verlag KG
Weitere therapeutische Verfahren
- 5 December 2022
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (S1) , 81-88
The German Lipoprotein Apheresis Registry—Summary of the ninth annual report
During 2012–2020, 89 German apheresis centers collected retrospective and prospective observational data of 2028 patients undergoing regular lipoprotein apheresis (LA) for the German Lipoprotein Apheresis Registry (GLAR). More than 47 500 LA sessions are documented in GLAR. In 2020, all patients treated with LA showed a high immediate median reduction rate of LDL‐C (68.2%, n = 1055) and Lp(a) (72.4%, n = 994). Patient data were analyzed for the incidence rate of major coronary events (MACE) 1 and 2 years before the beginning of LA treatment (y‐2 and y‐1) and prospectively up to 7 years on LA (y + 1 to y + 7). During the first 2 years of LA (y + 1 and y + 2), a MACE reduction of 78% was observed. Current analysis of GLAR data shows very low incidence rates of cardiovascular events in patients with high LDL‐C and/or high Lp(a) levels, progressive ASCVD, and maximally tolerated lipid lowering medication regular by LA results.
- 5 December 2022
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 26 (S1) , 81-88
The German Lipoprotein Apheresis Registry—Summary of the ninth annual report
During 2012–2020, 89 German apheresis centers collected retrospective and prospective observational data of 2028 patients undergoing regular lipoprotein apheresis (LA) for the German Lipoprotein Apheresis Registry (GLAR). More than 47 500 LA sessions are documented in GLAR. In 2020, all patients treated with LA showed a high immediate median reduction rate of LDL‐C (68.2%, n = 1055) and Lp(a) (72.4%, n = 994). Patient data were analyzed for the incidence rate of major coronary events (MACE) 1 and 2 years before the beginning of LA treatment (y‐2 and y‐1) and prospectively up to 7 years on LA (y + 1 to y + 7). During the first 2 years of LA (y + 1 and y + 2), a MACE reduction of 78% was observed. Current analysis of GLAR data shows very low incidence rates of cardiovascular events in patients with high LDL‐C and/or high Lp(a) levels, progressive ASCVD, and maximally tolerated lipid lowering medication regular by LA results.
- Open Access
- 30 September 2022
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (1) , 119-129
Novel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study
Aim: The PERI-DYS study aims to characterize two groups of patients with dyslipidaemia at very high CV risk: PCSK9i receivers and patients qualifying for but not receiving PCSK9i. Methods: This is an observational study by office-based and clinic-based physicians, mainly cardiologists and other internists in Germany, with data extracted from patient charts. ClinicalTrials.gov identifier NCT03110432. Results: A total of 1659 patients were enrolled across 70 sites. The majority of patients (91.0%) were reported as having mixed dyslipidaemia or non-familial or heterozygous familial hypercholesterolemia. At enrolment, 794 (47.9%) of patients were PCSK9i receivers (of these 65.9% ongoing, and 34.1% newly treated within 30 days before their baseline visit). Among PCSK9i receivers, the majority had evolocumab 140 mg (n = 632, 38.1% of total). PCSK9i receivers compared to non-receivers were about 2 years younger and had a lower proportion of males. In terms of comorbidities, they had (statistically significantly) more often CAD, and less often PAD, diabetes mellitus, arterial hypertension and chronic renal disease. The calculated untreated median LDL-C was 187 mg/dl (IQR 127; 270) in ongoing PCSK9i receivers, 212 mg/dl (IQR 132; 277) in newly treated PCSK9i receivers, and 179 mg/dl (IQR 129; 257) in non-receivers. Physician-reported statin intolerance was much more common in the two PCSK9i receiver groups as compared to non-receivers (67.3% versus 15.3%). Consequently, patients in the PCSK9i groups received fewer concomitant statins. Mean total cholesterol (143 vs. 172 mg/dl) and LDL-C (69 vs. 99 mg/dl) were considerably lower in ongoing PCSK9i receivers compared to non-receivers. Conclusions: PCSK9i receivers are characterized by higher baseline LDL-C and a higher portion of statin intolerance compared to those qualified for but not-receiving PCSK9i treatment. On-treatment, LDL-C was lower in PCSK9i receivers. Ongoing follow-up will determine the prognostic importance of these findings.
- 30 September 2022
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 38 (1) , 119-129
Open AccessNovel Insights into the Management of Patients with Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: Baseline Findings from the PERI-DYS Study
Aim: The PERI-DYS study aims to characterize two groups of patients with dyslipidaemia at very high CV risk: PCSK9i receivers and patients qualifying for but not receiving PCSK9i. Methods: This is an observational study by office-based and clinic-based physicians, mainly cardiologists and other internists in Germany, with data extracted from patient charts. ClinicalTrials.gov identifier NCT03110432. Results: A total of 1659 patients were enrolled across 70 sites. The majority of patients (91.0%) were reported as having mixed dyslipidaemia or non-familial or heterozygous familial hypercholesterolemia. At enrolment, 794 (47.9%) of patients were PCSK9i receivers (of these 65.9% ongoing, and 34.1% newly treated within 30 days before their baseline visit). Among PCSK9i receivers, the majority had evolocumab 140 mg (n = 632, 38.1% of total). PCSK9i receivers compared to non-receivers were about 2 years younger and had a lower proportion of males. In terms of comorbidities, they had (statistically significantly) more often CAD, and less often PAD, diabetes mellitus, arterial hypertension and chronic renal disease. The calculated untreated median LDL-C was 187 mg/dl (IQR 127; 270) in ongoing PCSK9i receivers, 212 mg/dl (IQR 132; 277) in newly treated PCSK9i receivers, and 179 mg/dl (IQR 129; 257) in non-receivers. Physician-reported statin intolerance was much more common in the two PCSK9i receiver groups as compared to non-receivers (67.3% versus 15.3%). Consequently, patients in the PCSK9i groups received fewer concomitant statins. Mean total cholesterol (143 vs. 172 mg/dl) and LDL-C (69 vs. 99 mg/dl) were considerably lower in ongoing PCSK9i receivers compared to non-receivers. Conclusions: PCSK9i receivers are characterized by higher baseline LDL-C and a higher portion of statin intolerance compared to those qualified for but not-receiving PCSK9i treatment. On-treatment, LDL-C was lower in PCSK9i receivers. Ongoing follow-up will determine the prognostic importance of these findings.
- 4 December 2020
- Published by Frontiers Media SA in Transplant International
- Vol. 34 (2) , 378-381
Solid organ transplantation is not a risk factor for COVID‐19 disease outcome
Reports indicate an increased mortality risk for solid organ transplant recipients with COVID‐19 (1, 2), which may have been influenced by clinical decision making (triage) during the early phase of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic. In Germany, relatively few transplant recipients were infected, and the capacity of the health care system was at no point in time overwhelmed. Hereby, high capacity PCR‐testing including all potential organ donors, symptomatic organ recipients or other patients, as well as a relatively high number of hospitals with intensive care units (1248) as well as transplant centers (40) with high capacities allowed a completely unimpaired organ procurement and transplantation situation throughout the first wave of the pandemic despite having SARS‐CoV‐2 infection rates of app. 2200 per million persons at the end of May 2020. Our data lead to a different assessment of the risk associated with COVID‐19 after organ transplantation.
- 4 December 2020
- Published by Frontiers Media SA in Transplant International
- Vol. 34 (2) , 378-381
Solid organ transplantation is not a risk factor for COVID‐19 disease outcome
Reports indicate an increased mortality risk for solid organ transplant recipients with COVID‐19 (1, 2), which may have been influenced by clinical decision making (triage) during the early phase of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic. In Germany, relatively few transplant recipients were infected, and the capacity of the health care system was at no point in time overwhelmed. Hereby, high capacity PCR‐testing including all potential organ donors, symptomatic organ recipients or other patients, as well as a relatively high number of hospitals with intensive care units (1248) as well as transplant centers (40) with high capacities allowed a completely unimpaired organ procurement and transplantation situation throughout the first wave of the pandemic despite having SARS‐CoV‐2 infection rates of app. 2200 per million persons at the end of May 2020. Our data lead to a different assessment of the risk associated with COVID‐19 after organ transplantation.
- 3 September 2020
- Published by Springer Nature in Der Nephrologe
- Vol. 15 (6) , 356-362
Immunglobulin- und komplementvermittelte glomeruläre Erkrankungen mit MPGN-Muster
- 3 September 2020
- Published by Springer Nature in Der Nephrologe
- Vol. 15 (6) , 356-362
Immunglobulin- und komplementvermittelte glomeruläre Erkrankungen mit MPGN-Muster